What are the approved first‑line treatment options for HER2‑positive metastatic breast cancer?

HER2-Positive Metastatic Breast Cancer: First-Line Approved Treatments

The standard first-line treatment for HER2-positive metastatic breast cancer is trastuzumab plus pertuzumab plus a taxane (THP), unless the patient has a contraindication to taxanes. 1

Primary First-Line Regimen

Trastuzumab + Pertuzumab + Taxane is the established first-line therapy with:

• High-quality evidence supporting this combination 1
• Strong recommendation from ASCO guidelines (evidence quality: High, strength: Strong) 1
• Median progression-free survival of 26.9 months in recent data 2
• This regimen remains preferred in most clinical scenarios 3, 4, 5

Emerging First-Line Option

Trastuzumab deruxtecan (T-DXd) + Pertuzumab has recently demonstrated superiority over standard THP:

• Median PFS of 40.7 months vs 26.9 months with THP (hazard ratio 0.56; 95% CI 0.44-0.71; P<0.00001) 2
• Complete response rate of 15.1% vs 8.5% with THP 2
• Median duration of response 39.2 months vs 26.4 months 2
• This represents a 44% reduction in risk of progression or death compared to standard therapy 2

Important Safety Consideration for T-DXd

• Interstitial lung disease (ILD) occurred in 12.1% of patients receiving T-DXd + pertuzumab (grade 1-2 in 44 patients, grade 5 [fatal] in 2 patients) vs 1.0% with THP 2
• Grade 3+ adverse events in 63.5% with T-DXd + pertuzumab vs 62.3% with THP 2
• Requires careful monitoring for pulmonary symptoms throughout treatment 2

Special Population: HR-Positive/HER2-Positive Disease

For patients with hormone receptor-positive and HER2-positive metastatic breast cancer, three options exist:

1. HER2-targeted therapy plus chemotherapy (standard approach; evidence quality: High, strength: Strong) 1
2. Endocrine therapy plus trastuzumab or lapatinib (for selected cases; evidence quality: Moderate, strength: Strong) 1
3. Endocrine therapy alone (for highly selected cases; evidence quality: Intermediate, strength: Weak) 1

Maintenance Strategy for HR+/HER2+ Disease

• Palbociclib added to maintenance HER2-targeted and endocrine therapy after initial chemotherapy plus HER2-targeted therapy demonstrated median PFS of 44.3 months vs 29.1 months with standard maintenance (HR 0.75; P=0.02) 6
• This represents a 25% reduction in risk of progression 6
• Grade 3-4 neutropenia is the primary toxicity (79.7% grade 3,10.0% grade 4) 6

Treatment Duration and Sequencing

Chemotherapy should continue for 4-6 months (or longer) until maximal response, depending on toxicity and absence of progression 1

HER2-targeted therapy continues after chemotherapy discontinuation until progression or unacceptable toxicity 1

Recurrence Timing Considerations

• If recurrence ≤12 months after completing trastuzumab-based adjuvant therapy: Follow second-line treatment recommendations (consider T-DXd as first-line for metastatic disease) 1, 3
• If recurrence >12 months after completing trastuzumab-based adjuvant therapy: Use standard first-line metastatic treatment (THP or T-DXd + pertuzumab) 1

Biosimilar Equivalence

FDA-approved trastuzumab biosimilars (e.g., SB3) are appropriate substitutes for reference trastuzumab 7, 8

• Real-world data demonstrate comparable median PFS of 12.7 months with biosimilar SB3 plus pertuzumab 8
• Subcutaneous trastuzumab-hyaluronidase may substitute for intravenous trastuzumab with different dosing 7

Critical Pitfalls to Avoid

• Do not omit cardiac monitoring: Evaluate left ventricular ejection fraction prior to and every 3 months during trastuzumab therapy 7
• Do not use anthracycline-containing regimens routinely: Non-anthracycline regimens with trastuzumab and pertuzumab show equivalent efficacy with less cardiotoxicity and febrile neutropenia 7
• Do not delay treatment in patients with visceral crisis: These patients require immediate HER2-targeted therapy plus chemotherapy, not endocrine therapy alone 1
• Monitor for ILD symptoms if using T-DXd: cough, dyspnea, fever require immediate evaluation 2